File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy

TitleRelapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
Authors
Issue Date2009
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 2009, v. 50 n. 2, p. 289-295 How to Cite?
AbstractBackground/Aims: To evaluate the off-treatment durability of response in HBeAg-negative chronic hepatitis B patients who achieved a protocol-defined 'Response' (HBV-DNA < 0.7 MEq/mL and ALT < 1.25 × ULN) with entecavir at 48 weeks and the efficacy of entecavir in patients treated beyond one year. Methods: Entecavir-treated and lamivudine-treated patients who achieved a protocol-defined 'Response' were evaluated off-treatment for HBV-DNA < 300 copies/mL and ALT normalisation. Entecavir- and lamivudine-treated patients who achieved a protocol-defined 'Virological Response' (HBV-DNA < 0.7 MEq/mL but ALT ≥ 1.25 × ULN) at 48 weeks, continued blinded treatment until they achieved Response or 96 weeks, whichever came first. Results: Among 'Responders' who discontinued treatment after 48 weeks, 7/257 (3%) entecavir-treated and 10/201 (5%) lamivudine-treated patients sustained HBV-DNA below 300 copies/mL at 24-weeks off-treatment. Among the 54 patients who continued blinded treatment in the second year, 7/26 (27%) entecavir-treated and 6/28 (21%) lamivudine-treated patients normalised ALT and 22/26 (85%) entecavir-treated and 16/28 (57%) lamivudine-treated patients maintained HBV-DNA < 300 copies/mL at end-of-dosing. The safety profiles of both drugs remained comparable through a second year of treatment. Conclusions: The majority of protocol-defined Responders relapsed after 1 year when treatment was discontinued. Treatment with entecavir beyond 1 year provided continued virological and biochemical benefit. © 2008 European Association for the Study of the Liver.
Persistent Identifierhttp://hdl.handle.net/10722/163219
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorShouval, Den_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorChang, TTen_US
dc.contributor.authorCheinquer, Hen_US
dc.contributor.authorMartin, Pen_US
dc.contributor.authorCarosi, Gen_US
dc.contributor.authorHan, Sen_US
dc.contributor.authorKaymakoglu, Sen_US
dc.contributor.authorTamez, Ren_US
dc.contributor.authorYang, Jen_US
dc.contributor.authorTenney, Den_US
dc.contributor.authorBrettSmith, Hen_US
dc.date.accessioned2012-09-05T05:28:50Z-
dc.date.available2012-09-05T05:28:50Z-
dc.date.issued2009en_US
dc.identifier.citationJournal Of Hepatology, 2009, v. 50 n. 2, p. 289-295en_US
dc.identifier.issn0168-8278en_US
dc.identifier.urihttp://hdl.handle.net/10722/163219-
dc.description.abstractBackground/Aims: To evaluate the off-treatment durability of response in HBeAg-negative chronic hepatitis B patients who achieved a protocol-defined 'Response' (HBV-DNA < 0.7 MEq/mL and ALT < 1.25 × ULN) with entecavir at 48 weeks and the efficacy of entecavir in patients treated beyond one year. Methods: Entecavir-treated and lamivudine-treated patients who achieved a protocol-defined 'Response' were evaluated off-treatment for HBV-DNA < 300 copies/mL and ALT normalisation. Entecavir- and lamivudine-treated patients who achieved a protocol-defined 'Virological Response' (HBV-DNA < 0.7 MEq/mL but ALT ≥ 1.25 × ULN) at 48 weeks, continued blinded treatment until they achieved Response or 96 weeks, whichever came first. Results: Among 'Responders' who discontinued treatment after 48 weeks, 7/257 (3%) entecavir-treated and 10/201 (5%) lamivudine-treated patients sustained HBV-DNA below 300 copies/mL at 24-weeks off-treatment. Among the 54 patients who continued blinded treatment in the second year, 7/26 (27%) entecavir-treated and 6/28 (21%) lamivudine-treated patients normalised ALT and 22/26 (85%) entecavir-treated and 16/28 (57%) lamivudine-treated patients maintained HBV-DNA < 300 copies/mL at end-of-dosing. The safety profiles of both drugs remained comparable through a second year of treatment. Conclusions: The majority of protocol-defined Responders relapsed after 1 year when treatment was discontinued. Treatment with entecavir beyond 1 year provided continued virological and biochemical benefit. © 2008 European Association for the Study of the Liver.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Resistance, Viralen_US
dc.subject.meshGuanine - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshHepatitis B E Antigens - Blooden_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLamivudine - Therapeutic Useen_US
dc.subject.meshRecurrenceen_US
dc.subject.meshViral Loaden_US
dc.titleRelapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapyen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.jhep.2008.10.017en_US
dc.identifier.pmid19070393-
dc.identifier.scopuseid_2-s2.0-58149316191en_US
dc.identifier.hkuros181149-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58149316191&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume50en_US
dc.identifier.issue2en_US
dc.identifier.spage289en_US
dc.identifier.epage295en_US
dc.identifier.isiWOS:000263309000010-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridShouval, D=7006175997en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridChang, TT=7404725147en_US
dc.identifier.scopusauthoridCheinquer, H=6602829370en_US
dc.identifier.scopusauthoridMartin, P=7406037297en_US
dc.identifier.scopusauthoridCarosi, G=7102187567en_US
dc.identifier.scopusauthoridHan, S=8060394800en_US
dc.identifier.scopusauthoridKaymakoglu, S=7004155395en_US
dc.identifier.scopusauthoridTamez, R=25634823500en_US
dc.identifier.scopusauthoridYang, J=15039392900en_US
dc.identifier.scopusauthoridTenney, D=7006419890en_US
dc.identifier.scopusauthoridBrettSmith, H=7801442680en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats